Twitter Beğeni Hilesi

#OnTheBlog: For the first time since July, we're seeing slight increases in #COVID positivity, with highest growth in those 18-24 years old. Read about this, as well as, information about reinfections and coinfections with other viruses in our latest post bit.ly/3UNiLqJ

More signals of moderate surge in SF: UCSF Health asymptomatic test pos. rate now 3.7% (was ~2 last month); 32 Covid patients in my hospital (was 15), & wastewater rising. Overall, Covid risk from same encounter probably twice what it was on 11/1. Get boosted, rethink masks.

Great announcement for the end of the year!

NEW: We are working with the CDC to better understand the role of human #genetics in #vaccine effectiveness – particularly across #COVID19 variants – leveraging both our population genomics and viral surveillance expertise. Learn more here: bit.ly/3WKrsmF

#InTheNews This winter, the U.S. saw less COVID cases. Helix's shishi luo told Cecelia Smith at U.S. News & World Report a level of immunity played a role. Plus, recent variants are Omicron descendants, so the population hasn’t been exposed to a new strain of COVID-19. tinyurl.com/bdd5e4hu

Call for nominations! NASEM Health is seeking experts for a new consensus study, "The Use of Race and Ethnicity in #BiomedicalResearch." Learn more & submit by 7/15 here: ow.ly/3T6x50OUgNv #bioethics

#InTheNews: shishi luo, Head of Infectious Diseases, spoke w/MedPage Today about the BA.2.86 variant. "There is "reason to continue to monitor it. The key to the public health response is being able to connect sequencing data with clinical patient data." bit.ly/3Pi42DX

#OnTheBlog: New RWE analysis conducted with Pfizer Inc. analyzes the rate of viral SARS-CoV-2 rebound in those treated with NMV-r compared to untreated patients. Click here to learn whether they occurred at a higher rate or what their severity was like: bit.ly/3GCRt0N

Using tokenization, we were able to leverage our SARS-CoV-2 diagnostic testing data to create a cohort of over 30,000 individuals to answer an important clinical question: how frequent is SARS-CoV-2 rebound in the real world?

Great work from the team at Helix for getting this news out before the holidays and in time to have a clinical impact on the current surge in COVID-19 cases.

Check out what we achieved in 2023!

Congrats to Alexandre Bolze and coauthors on research demonstrating how personalized genetics can help defer breast cancer screening for those at low risk. Read the feature on GenomeWeb: genomeweb.com/sequencing/bre…

Great job by the The New York Times for highlighting the underutilization of SARS-CoV-2 antivirals. We've also seen low antiviral uptake rates (~20%) in Helix's viral monitoring data. Read more in our brief report published at Clinical Infectious Diseases academic.oup.com/cid/article-ab…

Great to see Helix 's research on infectious diseases picked up by the popular TWiV podcast (starts about the 27th minute)! COVID isn't likely to go away soon, and our work shows that more could be done to treat and prevent severe cases.

#InTheNews: @USNews spoke w/head of infectious diseases, shishi luo, about the winter COVID-19 wave, saying Helix’s data shows the benefits of COVID-19 vaccines among older populations and future vaccine campaigns might be more targeted to that age group. bit.ly/493UlA3

Join us in officially welcoming Hylton Kalvaria as SVP of Life Sciences. CEO James Lu said: “Strengthening our team with Hylton further positions Helix to ensure the power of genomics is used to improve healthcare outcomes on the largest possible scale.” bwnews.pr/3IxHsCM

Electric service has begun on the Caltrain corridor! And yes, there will be multiple trains today that will be electric! 🤭🫶🏼⚡️